Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Cartesian Therapeutics today and set a price target of $25.00. According to TipR...

H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LifeMD (LFMD), Corbus Pharmaceuticals (CRBP) and Car...

Analysts Are Bullish on These Healthcare Stocks: LifeMD (LFMD), Corbus Pharmaceuticals (CRBP)

Insiders have been trading these 5 stocks: (($JPM)), (($CVX)), (($MSTR)), (($MRNA)) and (($SNAP)). Here is a breakdown of their recent trades and t...

JPMorgan, Chevron, Strategy, Moderna, Snap Insider Shake-Up

An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On May 19, 2026, TransCode Therapeutics disclosed that it received a deficiency...

TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on Moderna, with a price target of $32.00. Acco...

Bank of America Securities Sticks to Its Sell Rating for Moderna (MRNA)

Moderna ( ($MRNA) ) has fallen by -7.26%. Read on to learn why. Moderna’s share price slipped 7.26% over the past week, as investors weighed headli...

Moderna Stock Stumbles as Vaccine Hype Meets Reality

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna and Merck Advance Personalized Lung Cancer Vaccine Trial The Phase 3 s...

Moderna and Merck Push Personalized Lung Cancer Vaccine Into Phase 3

The SPDR S&P 500 ETF Trust ($SPY) rose 0.56% today, May 13, as a strong rebound in AI and semiconductor stocks outweighed hotter-than-expected infl...

SPDR S&P 500 ETF Trust (SPY) Daily Update, 5/13/2026

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $45.00. The company’s shares closed yester...

Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)

U.S. pharma and biotech firm Moderna’s ($MRNA) shares climbed by about 9% in Monday’s pre-market session, extending their roughly 12% gain on Frida...

Moderna Stock (MRNA) Extends Breakout amid Hantavirus Fears

Moderna ( ($MRNA) ) has risen by 14.90%. Read on to learn why. Moderna shares climbed 14.90% over the past week as investors rushed into the stock ...

Moderna’s Hantavirus Hype Fuels Rally Amid Setbacks

The SPDR S&P 500 ETF Trust ($SPY) gained 0.83% today, May 8, at a record high. The ETF was lifted by strong gains in AI‑focused tech stocks and a b...

Why Is SPDR S&P 500 ETF Trust (SPY) Up Today, 5/8/2026?

The SPDR S&P 500 ETF Trust ($SPY) fell 0.31% today, May 7, pulling back from record highs as investors took profits. Renewed uncertainty around U.S...

Why Is SPDR S&P 500 ETF Trust (SPY) Down Today, 5/7/2026?

In a report released yesterday, from Berenberg Bank maintained a Hold rating on Moderna, with a price target of $45.00. In addition to Berenberg Ba...

Berenberg Bank Sticks to Its Hold Rating for Moderna (MRNA)

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics will showcase multiple aspects of its Multiple System Atrophy...

Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cartesian Therapeutics (RNAC) and Tenax Therapeutics...

Wall Street Analysts Are Bullish on Top Healthcare Picks

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), gained 0.50% in Tuesday’s pre-market trading as solid corporate earnings and...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 5/5/2026?

The SPDR S&P 500 ETF Trust ($SPY) slipped 0.37% today, May 4, pulling back from record highs as rising tensions in the Middle East, particularly ar...

Why Is SPDR S&P 500 ETF Trust (SPY) Down Today, 5/4/2026?

The latest update is out from Eterna Therapeutics ( ($ERNA) ). On May 1, 2026, Ernexa Therapeutics Inc. filed a certificate of amendment in Delawar...

Eterna Therapeutics Implements 1-for-25 Reverse Stock Split

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), slipped 0.05% in Monday’s pre-market trading as new developments in the Midd...

Why Is Vanguard S&P 500 ETF (VOO) Sliding Today, 5/4/2026?

Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $48.00. According to TipRanks, Merle is a 3-star ...

Barclays Sticks to Their Hold Rating for Moderna (MRNA)

These are the upcoming stock splits for the week of May 4 to May 8, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate move aim...

Upcoming Stock Splits This Week (May 4 to May 8) – Stay Invested

Moderna (($MRNA)) has held its Q1 earnings call. Read on for the main highlights of the call. Moderna’s latest earnings call struck a cautiously op...

Moderna Earnings Call: Revenue Rebound, Legal Overhang

The SPDR S&P 500 ETF Trust ($SPY) gained 0.28% today, May 1, reaching a new record high. The upside was driven by strong quarterly earnings from Ap...

Why Is SPDR S&P 500 ETF Trust (SPY) Up Today, 5/1/2026?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Stryker (SYK). Moderna (MRNA) In a report rele...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Stryker (SYK)

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), rose 0.30% in Friday’s pre-market trading, led by a 3% jump in Apple ($AAPL)...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 5/1/2026?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merit Medical Systems (MMSI), Alterity Therapeutics (ATHE) and Mo...

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Alterity Therapeutics (ATHE) and Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM). Illumina (ILMN...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC) and Humana (HUM). Ca...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)

The SPDR S&P 500 ETF Trust ($SPY) gained 0.96% today, April 30. Positive earnings reports from some major companies, including Alphabet ($GOOGL), h...

Why Is SPDR S&P 500 ETF Trust (SPY) Up Today, 4/30/2026?

On Friday, May 1, Chevron ($CVX), Exxon Mobil ($XOM), and Moderna ($MRNA) will report their earnings. All three companies will report before the ma...

Polymarket Earnings: Will CVX, XOM, MRNA Beat Earnings Tomorrow?

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cartesian Therapeutics (RNAC), Cadrenal Therapeutics...

Analysts Are Bullish on Top Healthcare Stocks: Cartesian Therapeutics (RNAC), Cadrenal Therapeutics, Inc. (CVKD)

The SPDR S&P 500 ETF Trust ($SPY) declined 0.02% today, April 29, as investors weighed big earnings reports, rising energy prices from geopolitical...

Why Is the SPY ETF Down Today, 4/29/2026?

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has called a virtual General Meeting of shareholders to be ...

Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026

The SPDR S&P 500 ETF Trust ($SPY) gained 0.17% today, April 27, lifted by ongoing optimism about AI stocks, anticipation of major tech earnings, an...

Why Is the SPY ETF Up Today, 4/27/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), slipped 0.04% in pre-market trading on Monday amid stalled talks between the...

Market Cap	$8.98B	P/E Ratio	NaN
52W High	$16.77	52W Low	$11.95
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-0.5%	52W Position	23.0%
Overall Score	38	Value Score	40
Quality Score	39	Technical Score	36

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$13.06	-0.23%	170.91K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$13.06	-0.2%	170.91K
3
4
5
6

RNA

RNA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel